Search MXCT
MAXCYTE, INC.
Nasdaq · CIK 1287098
Last close1.07
Daily change-0.02 (-1.83%)
10 Years gain-93.71%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MXCT · STANDARD
SIC 8731 · Services-Commercial Physical & Biological Research · Fiscal year end 1231
Fundamental
27.4Momentum
77.3Acceleration
86.4Confidence
89.0Annual Revenue7
Quarterly Revenue19
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality4.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics5.5 / 10
Forward Indicators2.2 / 5
Signals
Operating leverageOperating margin improved by 5.4686 percentage points.
ROIC expansionROIC improved by 11.1744 percentage points.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 24.8823 percentage points.
Key Metrics
Revenue Growth TTM-9.31%OK
Revenue CAGR 3Y-10%OK
Gross Margin130.38%OK
Operating Margin-225.5%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-51.44%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.82%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $20.96M | $26.80M | -$51.90M | -$34.41M | -$36.18M | 127.9% | -247.64% | -172.63% | -68.21% | 106.43M |
| 2025 FY Dec 31, 2024 | $22.22M | $31.53M | -$51.20M | -$27.61M | -$29.26M | 141.92% | -230.46% | -131.72% | -69.95% | 104.85M |
| 2024 FY Dec 31, 2023 | $19.50M | $36.55M | -$48.30M | -$21.69M | -$25.39M | 187.44% | -247.73% | -130.2% | -84.32% | 103.27M |
| 2023 FY Dec 31, 2022 | $28.75M | $39.16M | -$27.36M | -$14.78M | -$33.26M | 136.23% | -95.18% | -115.7% | -125.37% | 101.7M |
| 2022 FY Dec 31, 2021 | $21.57M | $30.25M | -$18.19M | -$10.68M | -$14.51M | 140.22% | -84.32% | -67.28% | -454.87% | 90.62M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $19.86M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-095971, 0001104659-25-111396 |
| Revenue Growth TTM | -9.31% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-095971, 0001104659-25-111396 |
| Revenue CAGR 3Y | -10% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-034557 |
| Revenue CAGR 5Y | 6.28% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-034557 |
| Gross Profit CAGR 3Y | -11.87% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-034557 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-095971, 0001104659-25-111396 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 130.38% | Gross Profit / Revenue | OK | 0001104659-26-095971, 0001104659-25-111396 |
| Operating Margin | -225.5% | Operating Income / Revenue | OK | 0001104659-26-095971, 0001104659-25-111396 |
| ROIC | -51.44% | NOPAT / Average Invested Capital | OK | 0001104659-26-095971, 0001104659-25-111396 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-095971 |
| Current Ratio | 12.26x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.19 | Revenue / Diluted Shares | OK | 0001104659-26-095971, 0001104659-25-111396 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |